Skip to main content

Table 2 Scenario analyses

From: Improving inhaler adherence in patients with Chronic Obstructive Pulmonary Disease: a cost-effectiveness analysis

Effects on exacerbations last (years)

Time horizon (years)

Hospital-treated exacerbations

Usual care

PHARMACOP

Prevented

Basecase scenario (effects last for 3 months)

0.25

1

0.24

0.18

0.07

Different time horizon

0.25

0.25

0.10

0.02

0.07

0.25

0.5

0.14

0.07

0.07

0.25

2

0.42

0.35

0.07

0.25

5

0.93

0.86

0.07

0.25

10

1.60

1.53

0.07

0.25

12.5

1.82

1.75

0.07

Different program run time (effects linear extrapolated)

1

1

0.24

0.06

0.18

5

5

0.93

0.23

0.70

12.5

12.5

1.82

0.46

1.36

Effect of adherence improvement lasts 2 years

0.25

5

0.93

0.86

0.07

Effect of adherence improvement lasts 12.5 years

0.25

12.5

1.82

1.75

0.07

Mean FEV 1 % pred of 40

0.25

1

0.25

0.18

0.07

0.25

5

1.02

0.95

0.07

0.25

10

1.75

1.68

0.07

Mean FEV 1 % pred of 60

0.25

1

0.22

0.15

0.07

0.25

5

0.84

0.77

0.07

0.25

10

1.44

1.37

0.07

Lower 95% CI RR effect on hospital treated exacerbations (RR = 0.121)

0.25

1

0.24

0.15

0.08

Upper 95% CI RR effect on hospital treated exacerbations (RR = 0.523)

0.25

1

0.24

0.19

0.05